Esperion Is Sitting On A Potential Blockbuster Drug (NASDAQ:ESPR) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Daiichi Sankyo Europe GmbH: Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
By Sabela Ojea Esperion Therapeutics and Daiichi Sankyo Europe GmbH said they have settled their pending commercial litigation and agreed on a $125 million.
– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II variation approval of NILEMDO® Tablet and NUSTENDI® Tablet.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo Co., Ltd.(OTC: